Ibogaine; authorize MSDH to select a consortium to conduct a drug development clinical trial to secure FDA's approval of.
Impact
If enacted, SB2561 could significantly impact state law regarding the use of ibogaine, a psychoactive substance, for medical purposes. The bill requires the designated consortium to apply for an Investigational New Drug (IND) application with the FDA and to pursue a breakthrough therapy designation. It mandates detailed reporting and matching fund requirements, reinforcing that the state will only provide funding upon verification that the consortium can secure additional financial backing from non-state sources.
Summary
Senate Bill 2561 is known as the Ibogaine Drug Development Clinical Trial Act. This bill aims to authorize the establishment of a consortium that will be responsible for conducting a clinical trial to secure FDA approval for ibogaine as a treatment for opioid use disorder, as well as co-occurring substance use disorders and other neurological or mental health conditions. The bill outlines the specific entities that must be involved in this consortium, including drug developers, institutions of higher learning, and hospitals, emphasizing the necessity of collaboration for successful drug development.
Contention
The bill is poised to generate discussion surrounding the implications of using ibogaine in clinical settings, particularly regarding safety and ethical considerations in its application for treating substance use disorders. With thorough administrative requirements outlined for trial conduct, there is potential for debate on the allocation of revenues generated from any intellectual property arising from the drug development process. Furthermore, provisions for supervising ibogaine treatment by licensed physicians may also be scrutinized in both professional and public health circles.
Establishes three-year nonpublic school pupil transportation pilot program in Ocean County to provide funding to county consortium of nonpublic schools that will assume responsibility for mandated nonpublic school busing.
Expands eligible grantees under New Jersey Civic Information Consortium; establishes provisions for tracking and reporting progress of grantee; requires grantee to post statement on Internet website.